Genetic Vaccines and Therapy (Genet Vaccine Ther)
Genetic Vaccines and Therapy is an Open Access, peer-reviewed, online journal dedicated to applying new knowledge about genetics in treating human disease. Genetic Vaccines and Therapy is aimed at researchers, clinicians and biotechnologists, worldwide, in the field of gene-based therapy and drug delivery. Examples of current topics of interest include: development of new biocompatible delivery materials, design of effective and safe vectors, exploration of new strategies for targeting drugs, and application of siRNA gene silencing to specific disease therapies. The field of genetic therapy is just beginning to see an increase in interest and applicability in the pharmaceutical and biotechnology community, and we have positioned this journal to meet the needs of workers in this new and highly promising area. Our goal in creating this new journal was to provide a platform for materials scientists and gene-delivery specialists, to come together with researchers and clinicians to explore new ways of combating disease by using DNA-based therapeutic agents. Traditional gene therapy has been aimed primarily at correcting hereditary problems; our focus is more broad, including the use of gene expression vectors for the endogenous production of factors designed to interfere with a wide range of diseases, including: asthma, viral infection, cancer and Alzheimer's disease. We hope that our efforts will be rewarded by an increased awareness of the tremendous medical potential of gene-based therapeutics, and an accelerated application of these materials to the prevention and treatment of a host of diseases.
Current impact factor: 2.10
Impact Factor Rankings
|Website||Genetic Vaccines and Therapy website|
|Material type||Document, Periodical, Internet resource|
|Document type||Internet Resource, Computer File, Journal / Magazine / Newspaper|
- Author can archive a pre-print version
- Author can archive a post-print version
- Publisher's version/PDF may be used
- Eligible UK authors may deposit in OpenDepot
- Creative Commons Attribution License
- Copy of License must accompany any deposit.
- All titles are open access journals
- 'BioMed Central' is an imprint of 'Springer Verlag (Germany)'
Publications in this journal
- SourceAvailable from: PubMed Central[Show abstract] [Hide abstract]
ABSTRACT: Peptide/DNA complexes have great potential as non-viral methods for gene delivery. Despite promising results for peptide-mediated gene delivery technology, an effective systemic peptide-based gene delivery system has not yet been developed. This study used pCMV-Luc as a model gene to investigate the biodistribution and the in vivo efficacy of arginine peptide-mediated gene delivery by polymerase chain reaction (PCR). Plasmid DNA was detected in all organs tested 1 h after intraperitoneal administration of arginine/DNA complexes, indicating that the arginine/DNA complexes disseminated widely through the body. The plasmid was primarily detected in the spleen, kidney, and diaphragm 24 h post administration. The mRNA expression of plasmid DNA was noted in the spleen, kidney, and diaphragm for up to 2 weeks, and in the other major organs, for at least 1 week. Blood clearance studies showed that injected DNA was found in the blood as long as 6 h after injection. Taken together, our results demonstrated that arginine/DNA complexes are stable in blood and are effective for in vivo gene delivery. These findings suggest that intraperitoneal administration of arginine/DNA complexes is a promising tool in gene therapy.Genetic Vaccines and Therapy 08/2011; 9:13. DOI:10.1186/1479-0556-9-13
- [Show abstract] [Hide abstract]
ABSTRACT: Antigen presentation by non professional antigen presenting cells (APC) can lead to anergy. In genetic vaccines, targeting the macrophages and APC for efficient antigen presentation might lead to balanced immune response. One such approach is to incorporate APC specific promoter in the vector to be used. Three promoters known to be active in macrophage were selected and cloned in mammalian expressing vector (pAcGFP1-N1) to reconstruct (pAcGFP-MS), (pAcGFP-EMR) and (pAcGFP-B5I) with macrosialin, EmrI and Beta-5 Integrin promoters respectively. As a positive control (pAcGFP-CMV) was used with CMV promoter and promoterless vector (pAcGFP-NIX) which served as a negative control. GFP gene was used as readout under the control of each of the promoter. The expression of GFP was analyzed on macrophage and non-macrophage cell lines using Flow cytometry and qRT-PCR with TaqMan probe chemistries. All the promoters in question were dominant to macrophage lineage cell lines as observed by fluorescence, Western blot and quantitative RT-PCR. The activity of macrosialin was significantly higher than other macrophage promoters. CMV promoter showed 1.83 times higher activity in macrophage cell lines. The expression of GFP driven by macrosialin promoter after 24 hours was 4.40 times higher in macrophage derived cell lines in comparison with non macrophage cell lines. Based on this study, macrosialin promoter can be utilized for targeting macrophage dominant expression. In vivo study needs to be carried out for its utility as a vaccine candidate.Genetic Vaccines and Therapy 06/2011; 9(1):10. DOI:10.1186/1479-0556-9-10
- [Show abstract] [Hide abstract]
ABSTRACT: RNAi gene therapies for HIV-1 will likely need to employ multiple shRNAs to counter resistant strains. We evaluated 3 shRNA co-expression methods to determine their suitability for present use; multiple expression vectors, multiple expression cassettes and single transcripts comprised of several dsRNA units (aka domains) with each being designed to a different target. Though the multiple vector strategy was effective with 2 shRNAs, the increasing number of vectors required is a major shortcoming. With single transcript configurations we only saw adequate activity from 1 of 10 variants tested, the variants being comprised of 2 - 3 different target domains. Whilst single transcript configurations have the most advantages on paper, these configurations can not yet be rapidly and reliably re-configured for new targets. However, our multiple cassette combinations of 2, 3 and 4 (29 bp) shRNAs were all successful, with suitable activity maintained in all positions and net activities comparable to that of the corresponding single shRNAs. We conclude that the multiple cassette strategy is the most suitably developed for present use as it is easy to design, assemble, is directly compatible with pre-existing shRNA and can be easily expanded.Genetic Vaccines and Therapy 04/2011; 9(1):9. DOI:10.1186/1479-0556-9-9
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.